Compare ANAB & PRGS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ANAB | PRGS |
|---|---|---|
| Founded | 2005 | 1981 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Computer Software: Prepackaged Software |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.6B |
| IPO Year | 2015 | 1995 |
| Metric | ANAB | PRGS |
|---|---|---|
| Price | $47.64 | $44.33 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 8 | 5 |
| Target Price | ★ $87.25 | $56.20 |
| AVG Volume (30 Days) | 447.0K | ★ 459.0K |
| Earning Date | 11-17-2026 | 09-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 91.02 | 7.79 |
| EPS | N/A | ★ 1.58 |
| Revenue | $234,603,000.00 | ★ $397,572,000.00 |
| Revenue This Year | N/A | $7.13 |
| Revenue Next Year | $69.42 | $22.19 |
| P/E Ratio | ★ N/A | $28.41 |
| Revenue Growth | ★ 157.01 | N/A |
| 52 Week Low | $30.27 | $23.82 |
| 52 Week High | $73.30 | $47.25 |
| Indicator | ANAB | PRGS |
|---|---|---|
| Relative Strength Index (RSI) | 44.91 | 56.13 |
| Support Level | $44.38 | $42.21 |
| Resistance Level | $51.94 | $43.98 |
| Average True Range (ATR) | 2.27 | 1.61 |
| MACD | 0.25 | 0.16 |
| Stochastic Oscillator | 44.55 | 63.28 |
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).
Progress Software Corp provides software products that enable customers to develop, deploy, and manage AI-powered applications and digital experiences. The Company operates across North America, Latin America, Europe, the Middle East and Africa (EMEA), and Asia Pacific through subsidiaries and distributors, generating a majority of its revenue from the United States. Its product portfolio includes Progress Agentic RAG, Automate MFT, Chef, Corticon, DataDirect, Developer Tools, Flowmon, Kemp LoadMaster, MarkLogic, MOVEit, OpenEdge, Semaphore, ShareFile, Sitefinity, and WhatsUp Gold, offering solutions for application development, data connectivity, DevOps automation, managed file transfer, network security, and digital experience. It generates maximum revenue from the United States.